These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 36303184)
1. Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes. Liu Z; Guo Y; Huang L; Jia Y; Liu H; Peng F; Duan L; Zhang H; Fu R Cell Commun Signal; 2022 Oct; 20(1):169. PubMed ID: 36303184 [TBL] [Abstract][Full Text] [Related]
2. Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT/CD155 pathway. Yue J; Li J; Ma J; Zhai Y; Shen L; Zhang W; Li L; Fu R Hematology; 2023 Dec; 28(1):2166333. PubMed ID: 36651499 [TBL] [Abstract][Full Text] [Related]
3. 161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS. Sarhan D; Brandt L; Felices M; Guldevall K; Lenvik T; Hinderlie P; Curtsinger J; Warlick E; Spellman SR; Blazar BR; Weisdorf DJ; Cooley S; Vallera DA; Önfelt B; Miller JS Blood Adv; 2018 Jun; 2(12):1459-1469. PubMed ID: 29941459 [TBL] [Abstract][Full Text] [Related]
4. Blockade of the TIGIT-CD155/CD112 axis enhances functionality of NK-92 but not cytokine-induced memory-like NK cells toward CD155-expressing acute myeloid leukemia. Seel K; Schirrmann RL; Stowitschek D; Ioseliani T; Roiter L; Knierim A; André MC Cancer Immunol Immunother; 2024 Jul; 73(9):180. PubMed ID: 38967649 [TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia. Kaito Y; Sugimoto E; Nakamura F; Tsukune Y; Sasaki M; Yui S; Yamaguchi H; Goyama S; Nannya Y; Mitani K; Tamura H; Imai Y Haematologica; 2024 Apr; 109(4):1107-1120. PubMed ID: 37731380 [TBL] [Abstract][Full Text] [Related]
6. Natural killer cell (NK) subsets and NK-like T-cell populations in acute myeloid leukemias and myelodysplastic syndromes. Aggarwal N; Swerdlow SH; TenEyck SP; Boyiadzis M; Felgar RE Cytometry B Clin Cytom; 2016 Jul; 90(4):349-57. PubMed ID: 26648320 [TBL] [Abstract][Full Text] [Related]
7. [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome]. Mi H; Fu R; Wang H; Qu W; Ruan E; Wang X; Wang G; Liu H; Wu Y; Song J; Xing L; Guan J; Li L; Jiang H; Zhang W; Yue L; Shao Z Zhonghua Yi Xue Za Zhi; 2014 Mar; 94(10):737-41. PubMed ID: 24844955 [TBL] [Abstract][Full Text] [Related]
8. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Epling-Burnette PK; Bai F; Painter JS; Rollison DE; Salih HR; Krusch M; Zou J; Ku E; Zhong B; Boulware D; Moscinski L; Wei S; Djeu JY; List AF Blood; 2007 Jun; 109(11):4816-24. PubMed ID: 17341666 [TBL] [Abstract][Full Text] [Related]
9. Natural Killer Cell Subpopulations and Inhibitory Receptor Dynamics in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cianga VA; Campos Catafal L; Cianga P; Pavel Tanasa M; Cherry M; Collet P; Tavernier E; Guyotat D; Rusu C; Aanei CM Front Immunol; 2021; 12():665541. PubMed ID: 33986753 [TBL] [Abstract][Full Text] [Related]
10. Terminal differentiation of bone marrow NK cells and increased circulation of TIGIT Zeng X; Yao D; Liu L; Zhang Y; Lai J; Zhong J; Zha X; Lu Y; Jin Z; Chen S; Li Y; Xu L Asia Pac J Clin Oncol; 2022 Aug; 18(4):456-464. PubMed ID: 34811925 [TBL] [Abstract][Full Text] [Related]
11. Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome. Carlsten M; Baumann BC; Simonsson M; Jädersten M; Forsblom AM; Hammarstedt C; Bryceson YT; Ljunggren HG; Hellström-Lindberg E; Malmberg KJ Leukemia; 2010 Sep; 24(9):1607-16. PubMed ID: 20613786 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes. Meng F; Li L; Lu F; Yue J; Liu Z; Zhang W; Fu R Front Oncol; 2020; 10():1595. PubMed ID: 32903786 [TBL] [Abstract][Full Text] [Related]
13. Characterization of myelodysplastic syndromes hematopoietic stem and progenitor cells using mass cytometry. Bachas C; Duetz C; van Spronsen MF; Verhoeff J; Garcia Vallejo JJ; Jansen JH; Cloos J; Westers TM; van de Loosdrecht AA Cytometry B Clin Cytom; 2023 Mar; 104(2):128-140. PubMed ID: 35289472 [TBL] [Abstract][Full Text] [Related]
14. IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma. Chauvin JM; Ka M; Pagliano O; Menna C; Ding Q; DeBlasio R; Sanders C; Hou J; Li XY; Ferrone S; Davar D; Kirkwood JM; Johnston RJ; Korman AJ; Smyth MJ; Zarour HM Clin Cancer Res; 2020 Oct; 26(20):5520-5533. PubMed ID: 32591463 [TBL] [Abstract][Full Text] [Related]
15. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566 [TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function. Sarhan D; Wang J; Sunil Arvindam U; Hallstrom C; Verneris MR; Grzywacz B; Warlick E; Blazar BR; Miller JS JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32045384 [TBL] [Abstract][Full Text] [Related]
17. Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. Sarhan D; Cichocki F; Zhang B; Yingst A; Spellman SR; Cooley S; Verneris MR; Blazar BR; Miller JS Cancer Res; 2016 Oct; 76(19):5696-5706. PubMed ID: 27503932 [TBL] [Abstract][Full Text] [Related]
18. Special Education: Aplastic Anemia. Teramura M; Mizoguchi H Oncologist; 1996; 1(3):187-189. PubMed ID: 10387986 [TBL] [Abstract][Full Text] [Related]
19. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome. Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R Front Immunol; 2022; 13():1078421. PubMed ID: 36569863 [TBL] [Abstract][Full Text] [Related]
20. CD155 and CD112 as possible therapeutic targets of Kaito Y; Hirano M; Futami M; Nojima M; Tamura H; Tojo A; Imai Y Oncol Lett; 2022 Feb; 23(2):51. PubMed ID: 34992684 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]